BUY Conviction4/5 Analysis quality75/100 now
The speaker highlights Beam Therapeutics' adenine base editor, which recently received FDA clearance for a clinical trial. They are collaborating with Verve Therapeutics to use base editing to treat hypercholesterolemia, initially targeting high-risk patients. If proven safe and efficacious, this technology could be expanded to a broader population, potentially making a significant dent in heart disease, the leading cause of death.
“the adenine based editor that's actually the base editor that recently uh a form of which recently received FDA clearance to begin a clinical trial uh led by beam therapeutics”